IL160965A0 - Method of treating hepatitis virus infection with a multiphasic interferon delivery profile - Google Patents

Method of treating hepatitis virus infection with a multiphasic interferon delivery profile

Info

Publication number
IL160965A0
IL160965A0 IL16096502A IL16096502A IL160965A0 IL 160965 A0 IL160965 A0 IL 160965A0 IL 16096502 A IL16096502 A IL 16096502A IL 16096502 A IL16096502 A IL 16096502A IL 160965 A0 IL160965 A0 IL 160965A0
Authority
IL
Israel
Prior art keywords
multiphasic
virus infection
hepatitis virus
delivery profile
treating hepatitis
Prior art date
Application number
IL16096502A
Other languages
English (en)
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of IL160965A0 publication Critical patent/IL160965A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
IL16096502A 2001-10-05 2002-09-26 Method of treating hepatitis virus infection with a multiphasic interferon delivery profile IL160965A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32774401P 2001-10-05 2001-10-05
PCT/US2002/030837 WO2003030923A1 (en) 2001-10-05 2002-09-26 Method of treating hepatitis virus infection with a multiphasic interferon delivery profile

Publications (1)

Publication Number Publication Date
IL160965A0 true IL160965A0 (en) 2004-08-31

Family

ID=23277854

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16096502A IL160965A0 (en) 2001-10-05 2002-09-26 Method of treating hepatitis virus infection with a multiphasic interferon delivery profile

Country Status (15)

Country Link
US (2) US20050063949A1 (hu)
EP (1) EP1450838A4 (hu)
JP (1) JP2005508943A (hu)
KR (1) KR20050030886A (hu)
CN (1) CN1738635A (hu)
AR (1) AR036728A1 (hu)
BR (1) BR0213103A (hu)
CA (1) CA2460690A1 (hu)
HU (1) HUP0401818A2 (hu)
IL (1) IL160965A0 (hu)
MX (1) MXPA04003238A (hu)
NO (1) NO20041814L (hu)
PL (1) PL369870A1 (hu)
WO (1) WO2003030923A1 (hu)
ZA (1) ZA200402236B (hu)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2427194A1 (en) 2000-11-03 2002-05-10 Biomedicines, Inc. Method for short-term and long-term drug dosimetry
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
EP1561470A1 (en) * 2003-06-20 2005-08-10 Innogenetics N.V. HCV vaccines comprising the envelope-1 (E1) protein or the corresponding DNA and at least one antiviral agent
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
ES2351527T3 (es) 2006-05-30 2011-02-07 Intarcia Therapeutics, Inc Modulador de flujo en dos piezas con conducto interno para un sistema osmótico de administración.
NZ574524A (en) 2006-08-09 2011-07-29 Intarcia Therapeutics Inc Piston assembly for positioning lumen of a reservoir for an osmotic delivery having a columnar body and a spring
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
JP5323832B2 (ja) 2007-08-07 2013-10-23 アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー 酸性水溶液中にｇｄｆ−５を含むタンパク質製剤
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US20090246171A1 (en) * 2008-03-27 2009-10-01 Van Antwerp William P Automatic system for dose control in treating hepatitis c using infusion pumps
US20110184379A1 (en) * 2008-03-27 2011-07-28 Medtronic, Inc. Method and system to define patient specific therapeutic regimens by means of pharmacokinetic and pharmacodynamic tools
CA2720845A1 (en) 2008-04-14 2009-10-22 Advanced Technologies And Regenerative Medicine, Llc Liquid buffered gdf-5 formulations
US9561214B2 (en) * 2008-10-16 2017-02-07 Array Biopharma Inc. Method of treatment using inhibitors of mitosis
WO2011014882A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS
LT2462246T (lt) 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
CN102711871A (zh) 2010-06-16 2012-10-03 麦德托尼克公司 用于稳定药物递送装置中的药物的阻尼系统
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
GB2515941A (en) 2011-10-21 2015-01-07 Abbvie Inc Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon
EA201490836A1 (ru) 2011-10-21 2014-11-28 Эббви Инк. Комбинационное лечение (например, с abt-072 или abt-333) с помощью daa для применения при лечении hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CN103071147A (zh) * 2011-10-26 2013-05-01 麦德托尼克公司 干扰素-α向乙型肝炎感染的患者的连续皮下施用
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
JP6993235B2 (ja) 2015-06-03 2022-01-13 インターシア セラピューティクス，インコーポレイティド インプラントの設置及び撤去システム
CN109689063A (zh) 2016-04-28 2019-04-26 埃默里大学 含有炔烃的核苷酸和核苷治疗组合物及其相关用途
EP3458084B1 (en) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5980884A (en) * 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
EP1023901A4 (en) * 1997-10-13 2004-10-27 Otsuka Pharma Co Ltd MEDICINES FOR HEPATITIS C AND THE USE THEREOF
US6824768B2 (en) * 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
US6245740B1 (en) * 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
CA2427194A1 (en) * 2000-11-03 2002-05-10 Biomedicines, Inc. Method for short-term and long-term drug dosimetry

Also Published As

Publication number Publication date
NO20041814L (no) 2004-06-11
ZA200402236B (en) 2005-03-22
AR036728A1 (es) 2004-09-29
US20050063949A1 (en) 2005-03-24
CN1738635A (zh) 2006-02-22
WO2003030923A1 (en) 2003-04-17
EP1450838A1 (en) 2004-09-01
US20090196853A1 (en) 2009-08-06
PL369870A1 (en) 2005-05-02
EP1450838A4 (en) 2005-09-28
MXPA04003238A (es) 2004-07-08
KR20050030886A (ko) 2005-03-31
HUP0401818A2 (hu) 2004-11-29
JP2005508943A (ja) 2005-04-07
CA2460690A1 (en) 2003-04-17
BR0213103A (pt) 2004-09-21

Similar Documents

Publication Publication Date Title
IL160965A0 (en) Method of treating hepatitis virus infection with a multiphasic interferon delivery profile
SI1414797T1 (sl) Inhibitorji polimeraze virusa hepatitisa c, ki imajo heterobicikliäśno struktuo
IL174796A0 (en) Methods for treating viral infection using-il-28 and il-29
EP1489416A4 (en) METHOD FOR THE EVALUATION OF VIRUS INFECTION
AU2002346686A1 (en) Compositions and method for treating hepatitis virus infection
AU2002343556A1 (en) Use of phosphonate nucleotide analogue for treating hepatitis b virus infections
AU2003216523A1 (en) Treatment of pre-core hepatitis b virus mutant infections
IL157251A0 (en) Hepatitis b virus treatment
IL162236A0 (en) Purified hepatitis c virus envelopeproteins for dagnostic and therapeutic use
EP1668145A4 (en) SENSE ANTIVIRUS COMPOUND AND METHOD FOR TREATING SSRNA VIRUS INFECTION
EP1485488A4 (en) RECOMBINANT EXPRESSION SYSTEMS FOR MINUSTRAN VIRUS RNA AND VACCINES
IL160881A0 (en) Method for treating hepatitis c virus infection in treatment failure patients
AU2001236938A1 (en) Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
AU2002324753A1 (en) Composition and method for treating viral infection
IL161138A0 (en) Treatment of hepatitis b virus infection with human monoclonal antibodies
AU2001269092A1 (en) Inhibitors of hepatitis b virus infection
EP1521849A4 (en) HEPATITIS A-VIRUS NUCLEOTIDE SEQUENCES, RECOMBINANT PROTEINS AND THEIR USE
IL160882A0 (en) Method for treating hepatitis c virus infection in treatment failure patients
AU2002365168A8 (en) Method and composition for treating and preventing hiv infection and aids
AU2001234596A1 (en) Use of castanospermine and substituted-castanospermine compounds for treating hepatitis virus infections
AU2003304040A8 (en) Anthranilic acid derivatives useful in treating infection with hepatitis c virus
ZA200402353B (en) Methods of treating liver fibrosis and hepatitis C virus infection
AU2003254129A8 (en) Method and composition for treating and preventing hepatitis b infection and symptoms thereof
EP1589994A4 (en) PREPARATION AND METHOD FOR PREVENTING OR TREATING VIRAL INFECTION
AU2001282560A1 (en) Methods of infection with hepatitis c virus